Latest California Healthline Stories
KFF Health News' 'What the Health?': Abortion and SCOTUS, Together Again
The Supreme Court agreed this week to hear its first major case on abortion since overturning Roe v. Wade — one that could restrict the availability of the abortion pill mifepristone, even in states where abortion remains legal. Meanwhile, on Capitol Hill, lawmakers in the House and Senate finally moved to renew health programs that expired in October — but it’s likely too late to finish the job in 2023. Alice Miranda Ollstein of Politico, Riley Griffin of Bloomberg News, and Lauren Weber of The Washington Post join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Jen Golbeck, a University of Maryland professor and social media superstar, about her new book, “The Purest Bond,” which lays out the science of the human-canine relationship.
Watch and Listen: Opioid Settlement Case Triggers Protests Outside the High Court
The Supreme Court heard arguments over whether the Sacklers, the family behind Purdue Pharma — which marketed OxyContin — could claim immunity from future lawsuits without claiming bankruptcy.
Gubernatorial Candidates Quarrel Over Glory for Winning Opioid Settlements
Some gubernatorial candidates are sparring over bragging rights for their state’s share of $50 billion in opioid settlement funds. Many of the candidates are attorneys general who pursued the lawsuits that produced the payouts.
KFF Health News' 'What the Health?': The New Speaker’s (Limited) Record on Health
The House finally has a new speaker: Mike Johnson (R-La). He’s a relative newcomer who’s been a lower-level member of the House GOP leadership. And while he’s an outspoken opponent of abortion and same-sex marriage, his record on other health issues is scant. Meanwhile, the National Institutes of Health appears on track to be getting a new director, and Georgia’s Medicaid work requirement experiment is off to a very slow start. Alice Miranda Ollstein of Politico and Rachel Cohrs of Stat join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Michael Cannon, director of health policy studies at the Cato Institute, a libertarian think tank.
Using Opioid Settlement Cash for Police Gear Like Squad Cars and Scanners Sparks Debate
State and local governments will receive a windfall of more than $50 billion over 18 years from settlements with companies that made, sold, or distributed opioid painkillers. Using the funds for law enforcement has triggered important questions about what the money was meant for.
Feds Try to Head Off Growing Problem of Overdoses Among Expectant Mothers
Homicides, suicides, and drug overdoses have driven rising rates of pregnancy-related death in the U.S. This fall, six states received federal funding for substance use treatment interventions to prevent at least some of those deaths.
Narcan, Now Available Without a Prescription, Can Still Be Hard to Get
Narcan is available without a prescription. Addiction treatment experts hope this move will increase access to the medication, which can reverse opioid overdoses. But hurdles remain: cost and stigma.
GOP Presidential Primary Debate No. 2: An Angry Rematch and the Same Notable No-Show
Though never framed as a marquee issue, the topic of health care crept into the chaotic seven-way faceoff throughout the evening, highlighting Republican culture-war themes.
Officials Agree: Use Settlement Funds to Curb Youth Addiction. But the ‘How’ Gets Hairy.
Parents, educators, and elected officials agree that investing in school-based prevention efforts could help curb the rising rate of youth drug overdoses. The well-known D.A.R.E. program is one likely choice, but its effectiveness is in question.
Artificial Intelligence May Influence Whether You Can Get Pain Medication
To contain the opioid crisis, health and law enforcement agencies have turned to technology to monitor doctor and patient prescription data. Experts have raised questions about how these systems work and worry about their accuracy and potential biases. Some patients and doctors say they’re being unfairly targeted.